Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services
March 28, 2019 08:30 ET
|
Canntab Therapeutics Limited
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. TORONTO, March 28, 2019 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE: PILL) (the “Company” or “Canntab”) is...
Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
February 28, 2019 07:00 ET
|
Canntab Therapeutics Limited
TORONTO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and...
Canntab Provides Corporate Update
February 19, 2019 23:30 ET
|
Canntab Therapeutics Limited
Moving into FSD Pharma and FSD Processing LicenseMackie Research ExtensionDirector Estate Planning InitiativeOTCQB under symbol CTABF TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Canntab Therapeutics...
Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
February 12, 2019 07:30 ET
|
Canntab Therapeutics Limited
TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules,...
Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets
December 05, 2018 08:00 ET
|
Canntab Therapeutics Limited
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with...
Canntab to Enter Medicinal Cannabis Market in Mexico
October 31, 2018 07:30 ET
|
Canntab Therapeutics Limited
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. Letter of Intent with Labsco Promedic SA de CV of MexicoExclusive Licensing of Canntab’s sustained release tablets...